clinical trial · NCT06867107
An Open-label Long-term Follow-up Study of SAT-3247 for Participants With Duchenne Muscular Dystrophy Including Those Who Participated in SAT-3247-CL-101
Satellos Bioscience, Inc.·phase2·enrolling by invitation·n = 10
Duchenne Muscular Dystrophy (DMD)SAT-3247
brief summary
This is an open-label long-term safety and efficacy study of orally administered SAT-3247 in patients with DMD that previously participated in SAT-3247-CL-101. The study will assess the long-term safety, tolerability and potential efficacy of long-term dosing of 60 mg of orally administered SAT-3247 in a 5-days on/2-days off (i.e. weekday dosing) regimen in an open-label design through 11 months- for a total of 12 months of treatment including the duration of the SAT-3247-CL-101 study. The study will enroll up to 10 participants that previously participated in the SAT-3247-CL-101 study.
started
Aug 20, 2025
primary completion
Aug 30, 2026
completion
Aug 30, 2026
last updated
Apr 23, 2026
official title
An Open-Label Long-Term Follow-up Study of SAT-3247 in Patients With Duchenne Muscular Dystrophy (DMD) Including Those Who Participated in SAT-3247-CL-101
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol